Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03210376
Other study ID # 2017-0046
Secondary ID NCI-2018-01176
Status Completed
Phase Phase 4
First received
Last updated
Start date November 17, 2017
Est. completion date October 22, 2020

Study information

Verified date November 2020
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Insufflation pressure (IP) is the creation of a pressure barrier of air/gas within the abdomen to allow the surgeon more space to work during abdominal surgery. Shoulder pain is a common complaint from patients who have had abdominal surgery and the pain is thought to be related to the use of IP. In addition to anesthesia (which keeps you asleep during surgery), the current standard practice is to block the nerve-muscle junction with a type of drug called neuromuscular blockade (NMB) which paralyzes the abdominal muscles. This means that a lower level of insufflation pressure is needed by the surgeon. To reverse the effects of NMB after surgery, a drug called neostigmine is given. The goal of this clinical research study is to compare the use of standard-of-care moderate NMB and neostigmine to the use of deep NMB and a drug called Sugammadex when given to elderly patients (patients who are 65 years of age or older) who are scheduled to have robotic abdominal surgery. "Deep" and "moderate" in this study refers to the dose or strength of the NMB given. This is an investigational study. Sugammadex and neostigmine are FDA approved and commercially available for the reversal of NMB. It is considered investigational to compare Sugammadex and neostigmine to learn if the use of one or the other in elderly patients can reduce the level of shoulder pain after surgery. Up to 100 participants will be enrolled in this study. All will take part at MD Anderson.


Description:

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups before your surgery. This is done because no one knows if one group is better, the same, or worse than the other. - In Group 1, you will receive deep NMB and Sugammadex. - In Group 2, you will receive moderate NMB and neostigmine. Neither you nor the surgeon or surgical staff will know to which group you have been assigned. The surgeon will not know which group you are in because researchers want to learn how much, if at all, the surgeon needs to adjust the insufflation pressure during surgery. However, if needed for your safety, the surgeon will be able to find out which group you are in. For your safety, the anesthesiologist will know to which group you have been assigned. Surgery and Study Drug Administration: After you have been assigned to a study group, you will have your surgery as scheduled. You will sign a separate consent form for surgery which describes the procedure and its risks in more detail. You will also sign a separate consent form to receive anesthesia. Before your surgery, blood (about 2 teaspoons) will be drawn for biomarker testing. Biomarkers are found in the blood/tissue and may be related to the status of the disease and/or your reaction to the study drug(s). During the surgery, the insufflation pressure that is being used, including any changes that are made to the pressure, will be recorded. After the surgery has been completed, you will receive either Sugammadex or neostigmine by vein until the effects of the NMB have been reversed. You will recover after surgery in the post-anesthesia care unit (PACU). At about 15, 45, and 90 minutes after your surgery, a PACU nurse will ask you about any shoulder pain you are feeling and if so, how intense the pain is. Information about how long you stay in the hospital after surgery and if you have any side effects after surgery (such as nausea/vomiting or shoulder pain) will also be collected from your medical record. Follow-Up: After 30 days after you leave the hospital, you will be called by a member of the study staff to ask how you are doing and if you have had any additional hospitalizations since leaving the hospital. This phone call should last about 5-10 minutes. Length of Study Participation: Your participation in this study will be over after completing the 30-day follow up phone call.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 22, 2020
Est. primary completion date September 30, 2018
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Patients 65 years of age or older 2. Patients having robotic prostatectomy 3. Written informed consent Exclusion Criteria: 1. Patient with known hypersensitivity to Rocuronium, Sugammadex or its components 2. Patients with severe renal insufficiency, defined and confirmed by an estimated creatinine clearance equal or lower than 30 mL/min, per institutional laboratory. 3. Patients with history of severe liver disease, defined as and confirmed by elevated ALT and AST greater than 1.5 times the Upper Limit of Normal along with Albumin less than 3 OR INR 1.5 or greater per institutional laboratory.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deep Neuromuscular Blockade (NMB)
Deep Neuromuscular Blockade (NMB) given during surgery.
Moderate Neuromuscular Blockade (NMB)
Moderate Neuromuscular Blockade (NMB) given during surgery.
Sugammadex
4 mg/Kg, intravenously as a single bolus injection after surgery.
Neostigmine
70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
Behavioral:
Pain Assessment
Pain assessment done at about 15, 45, and 90 minutes after surgery.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients Who Reported Shoulder Pain Visual Analog Scale (VAS) pain score (0-10) for shoulder pain recorded, where 0 means no pain and 10 means the worst pain ever experienced . Percentage of participants who experienced should pain. 30 days
Secondary Cumulative Intraoperative Insufflation Pressure Intra-abdominal insufflation time and pressure directed by the surgeon and recorded continuously by the clinical coordinator until the time of desufflation. Day 0 - IntraOperative-From beginning of pneumoperitoneum to desufflation (an average of 166 minutes)
Secondary Percentage of Muscle Response Using Train-of-Four (TOF) in Post-Anesthesia Care Unit (PACU) to Measure Residual Muscle Relaxation The patients will be started on a continuous Rocuronium intravenous infusion following intubation. Insert recommendations and Institutional Standards will be used for Rocuronium. For the DNMB group, the rate will be adjusted and boluses given to maintain 1-2 post tetanic responses during the pneumoperitoneum. NMB will be reversed with Sugammadex 4 mg/Kg, intravenously as a single bolus injection, at the end of the surgery. Percentage of measured contraction strength of the fourth stimulus compared to the first stimulus. Day 0 - Arrival time at PACU, an average of 3 minutes
Secondary Readiness to Discharge From the Post-Anesthesia Care Unit (PACU) Determined by the Dansk Selskab for Anæstesiologi og Intensiv Medicin(DASAIM)discharge criteria.Pts considered ready to discharge when the sum of all categories is<4 and no single category has a score of >1.Sedation.0:Patient is fully awake.1: Patient is asleep,aroused by verbal stimulation.2:Patient is asleep, aroused by physical stimulation.3:Patient is asleep,cannot be aroused.Respiratory Rate.0:Respiratory rate>10. 1: Snoring,10< RR<30. 2:R<10 or RR>30/min.3:Periods of apnea or obstructive patterns.Oxygen Saturation.0:SpO2 = 94%.1:90%=SpO2<94%. 2:85%= SpO2 < 90%.3:SpO2 < 85%. Systolic Blood Pressure. 0:SBP = 100mmHg.1:90mmHg=SBP< 100mmHg.2:80mmHg=SBP< 90mmHg or SBP>220mmHg.3:SBP<80mmHg.Heart Rate.0:50 Assessed at 15, 45, 90 minutes during PACU stay.
Secondary Percentage of Participants With Nausea and/or Vomiting in PACU Degree of Post-Operative Nausea determined per Visual Analog Scale per nurse in Post-Anesthesia Care Unit (PACU). Day 0 - PACU stay, an average of 120 minutes
Secondary Surgical Exposure Grading Day 0 - IntraOperative, from incision time to closing time(average 190 minutes)
Secondary Length of Hospital Stay length of hospital stay(average of 3 days)
See also
  Status Clinical Trial Phase
Withdrawn NCT02812056 - Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Phase 1
Active, not recruiting NCT02714439 - Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley Early Phase 1
Active, not recruiting NCT02774759 - Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers N/A
Recruiting NCT03093909 - Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Phase 1
Recruiting NCT02884648 - Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery Phase 2
Withdrawn NCT03128281 - Pneumoperitoneum Management With Low vs. Higher Pressure Phase 2
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Withdrawn NCT02915172 - Lenvatinib and Capecitabine in Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT03162627 - Selumetinib and Olaparib in Solid Tumors Phase 1
Terminated NCT02740114 - Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway Phase 3
Active, not recruiting NCT03531645 - Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma Phase 2